Ambulatory treatment of acute myeloid leukemia (AML) with weekly oral idarubicin alone in poor-risk elderly patients.

被引：0
|
作者：
Anglaret, B
Belhabri, A
Chelghoum, Y
Renaudier, P
Troncy, J
Bouheddou, N
Peaud, PY
Chevalier, MP
Thomas, X
机构：
[1] Ctr Hosp, Valence, France
[2] Hop Edouard Herriot, Lyon, France
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4621
引用
收藏
页码：208B / 208B
页数：1
相关论文
共 50 条
  • [1] A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients
    Bouabdallah, R
    Lefrère, F
    Rose, C
    Chaïbi, P
    Harousseau, JL
    Vernant, JP
    Castaigne, S
    Bauduer, F
    Zini, JM
    Coso, D
    Varet, B
    Robert, J
    Fenaux, P
    LEUKEMIA, 1999, 13 (10) : 1491 - 1496
  • [2] A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients
    R Bouabdallah
    F Lefrère
    C Rose
    P Chaïbi
    J-L Harousseau
    J-P Vernant
    S Castaigne
    F Bauduer
    J-M Zini
    D Coso
    B Varet
    J Robert
    P Fenaux
    Leukemia, 1999, 13 : 1491 - 1496
  • [3] FLUDARABINE, CYTARABINE AND IDARUBICIN FOR INDUCTION TREATMENT OF POOR-RISK ACUTE MYELOID LEUKEMIA
    Villa, M. R.
    Izzo, G. Nitrato
    Gagliardi, A.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 81 - 81
  • [4] ORAL IDARUBICIN AS SINGLE-AGENT TREATMENT OF ACUTE NONLYMPHOCYTIC LEUKEMIA IN POOR-RISK PATIENTS
    LOWENTHAL, RM
    CHESTERMAN, CN
    GRIFFITHS, JD
    MANOHARAN, A
    HARRIS, MG
    HERRMANN, RP
    ROONEY, KF
    ROZENBERG, MC
    SALEM, HHH
    WOLF, MM
    WOODRUFF, RE
    CANCER TREATMENT REPORTS, 1987, 71 (12): : 1279 - 1281
  • [5] Gentuzumab-ozogamicin (GO) plus idarubicin (I) and cytarabine (C) as induction treatment for elderly patients with poor-risk cytogenetics acute myeloid leukemia (AML)
    Harousseau, Jean-Luc
    Recher, Christian F. R.
    Vey, Norbert
    Witz, Francis
    Lioure, Bruno B. L.
    Toumilhac, Olivier
    Himberlin, Chantal
    Bouscary, Didier
    Ifrah, Norbert N. I.
    BLOOD, 2007, 110 (11) : 544A - 545A
  • [6] ORAL IDARUBICIN IN ELDERLY PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    KELDSEN, N
    KARLE, H
    HANSEN, NE
    NISSEN, NI
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1990, 45 (01) : 60 - 60
  • [7] TREATMENT OF ACUTE MYELOID-LEUKEMIA IN ELDERLY PATIENTS WITH ORAL IDARUBICIN AS A SINGLE AGENT
    HAROUSSEAU, JL
    RIGALHUGUET, F
    HURTELOUP, P
    GUY, H
    MILPIED, N
    PRIS, J
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1989, 42 (02) : 182 - 185
  • [8] Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia
    Russo, D
    Pricolo, G
    Michieli, M
    Michelutti, A
    Raspadori, D
    Bertone, A
    Marin, L
    Pierri, I
    Bucalossi, A
    Zuffa, E
    De Vivo, A
    Mazza, P
    Gobbi, M
    Lauria, F
    Zaccaria, A
    Baccarani, M
    LEUKEMIA & LYMPHOMA, 2001, 40 (3-4) : 335 - 343
  • [9] A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia
    Howard, Dianna S.
    Liesveld, Jane
    Phillips, Gordon L., II
    Hayslipa, John
    Weiss, Heidi
    Jordan, Craig T.
    Guzman, Monica L.
    LEUKEMIA RESEARCH, 2013, 37 (11) : 1502 - 1508
  • [10] A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)
    Howard, Dianna
    Liesveld, Jane
    Phillips, Gordon L., II
    Guzman, Monica L.
    Jordan, Craig T.
    BLOOD, 2008, 112 (11) : 1014 - 1014
12345